Abstract Library

#2894 Single Institution Experience with Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET)

Introduction: Neuroendocrine tumors (NETs) are a rare and heterogenous group of tumors with rising incidence. Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogue is an encouraging systemic treatment modality with minimum side effects.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Duan H

Authors: Duan H, Ninatti G, Girod B, Ferri V, Guja K,

Keywords: NET, PRRT, ORR, PFS,

#2788 Favourable Outcome in Patients with Metastatic Pheochromocytomas and Paragangliomas Treated with 177Lu-DOTATATE

Introduction: There is limited previous data on Peptide receptor radiotherapy (PRRT) in pheochromocytoma (PCC) and paraganglioma (PGL).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Vyakaranam A

Authors: Vyakaranam A, Crona J, Thiis-Evensen E, Hellman P, Norlén O,

Keywords: PRRT, 177Lu-DOTATATE, Pheochromocytoma, Paraganglioma,

#2218 More than Rare Pheochromocytomas: Bilateral and Hemorrhagic, Giant and Metastatic

Introduction: Pheochromocytomas (PCC) are rare neuroendocrine tumors. These catecholamine-secreting tumors, with an average size of 4.9cm, are multiple in 10% of cases. About 10% are malignant but distant metastases are rare. Non-traumatic adrenal hemorrhage is an unusual potentially fatal event seen in PCC.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Peralta Ferreira M

Authors: Peralta Ferreira M, Sousa Fernandes M, Roque R, Matos C, Strecht J,

Keywords: pheochromocytoma, giant, hemorrhagic, metastatic, bilateral,

#1489 The Clinical Utility of Blood Neuroendocrine Gene Transcript Analysis, the NETest, in Paragangliomas and Pheochromocytomas

Introduction: Diagnosis of disease and identification of progression are critical issues in paraganglioma (PGL) and pheochromocytoma (PCC) management. An accurate blood biomarker that defines tumor biology irrespective of biochemical activity is lacking.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Pęczkowska M

Authors: Cwikła J, Pęczkowska M, Kolasińska-Ćwikła A, Chiarelli J, Modlin I,

Keywords: NETest, PCR,

#1305 PRRT for Malignant Pheochromocytomas and Paragangliomas: The Singapore General Hospital Experience

Introduction: In recent years, the use of 177Lu-DOTATATE radioisotope therapy has been expanded to patients with metastatic pheochromocytomas and paragangliomas (PCC/PGL). Although this is not the standard of care, treatment options are limited for those with MIBG negative disease. Our centre has treated over 40 patients with NETS with PRRT since 2012.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Loh L, Lim D, Loke K, Ng D,

Keywords: PRRT, pheochromocytoma, paraganglioma,